US pharma major AbbVie today announced the submission of a Biologics License Application (BLA) to the US Food and Drug ...

Danish biotech Ascendis Pharma has announced new data demonstrating early, sustained, and clinically meaningful improvements ...

US pharma major Johnson & Johnson has reported Phase I results for JNJ-6143 (formerly HLD-0915), an investigational ...

US biotechnology EIT Pharma, which focused on advancing therapies for infectious diseases, today appointed Dr Jose Toerne as ...

Swiss pharma giant Novartis’ shares edged up 2% to 130.00 in early trading as the company reported third quarter 2026 ...

US clinical-stage biopharma Corxel Pharmaceuticals, which is focused on developing innovative oral therapies for obesity and ...

The diagnosed prevalent cases of ulcerative colitis (UC) in the seven major markets (7MM: The USA, France, Germany, Italy, ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a ...

China is emerging as an innovation hub in the rapidly diversifying global obesity drug landscape, with domestic drugmakers ...

German pharma and life sciences company Merck KGaA today announced new two-year follow-up results from the Phase III MANEUVER ...

The US Food and Drug Administration (FDA) has expanded approval of Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide ...

Chiesi Global Rare Diseases, the rare diseases business unit of Italy’s family-run Chiesi Group, announced three poster ...